Globus Medical Inc (NYSE:GMED) SVP Kelly Huller Sells 3,000 Shares

Globus Medical Inc (NYSE:GMED) SVP Kelly Huller sold 3,000 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $55.90, for a total transaction of $167,700.00. Following the sale, the senior vice president now owns 3,384 shares of the company’s stock, valued at approximately $189,165.60. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Kelly Huller also recently made the following trade(s):

  • On Friday, November 1st, Kelly Huller sold 3,000 shares of Globus Medical stock. The shares were sold at an average price of $52.90, for a total transaction of $158,700.00.

GMED traded up $0.17 during mid-day trading on Tuesday, reaching $55.24. 426,103 shares of the stock were exchanged, compared to its average volume of 576,873. The stock has a market capitalization of $5.52 billion, a PE ratio of 33.08, a price-to-earnings-growth ratio of 2.89 and a beta of 0.95. The company has a 50 day moving average price of $51.22 and a two-hundred day moving average price of $46.53. Globus Medical Inc has a 1 year low of $38.01 and a 1 year high of $56.34.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Wednesday, November 6th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.01. The firm had revenue of $196.22 million for the quarter, compared to the consensus estimate of $185.86 million. Globus Medical had a net margin of 19.03% and a return on equity of 13.09%. The business’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.39 EPS. On average, equities research analysts expect that Globus Medical Inc will post 1.72 earnings per share for the current fiscal year.

A number of analysts have commented on the stock. Wells Fargo & Co boosted their price target on shares of Globus Medical from $42.00 to $53.00 and gave the company a “market perform” rating in a research note on Tuesday, October 8th. BTIG Research restated a “hold” rating on shares of Globus Medical in a research note on Thursday, November 7th. Cantor Fitzgerald boosted their price target on shares of Globus Medical from $55.00 to $64.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Canaccord Genuity boosted their price target on shares of Globus Medical from $57.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Needham & Company LLC restated a “buy” rating and set a $63.00 price target on shares of Globus Medical in a research note on Thursday, November 7th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $59.00.

A number of institutional investors and hedge funds have recently bought and sold shares of GMED. Financial Gravity Wealth Inc. purchased a new position in Globus Medical during the 2nd quarter worth $25,000. Steward Partners Investment Advisory LLC purchased a new position in Globus Medical during the 2nd quarter worth $26,000. Advisory Services Network LLC boosted its holdings in Globus Medical by 620.0% during the 2nd quarter. Advisory Services Network LLC now owns 792 shares of the medical device company’s stock worth $34,000 after acquiring an additional 682 shares during the last quarter. Oakworth Capital Inc. purchased a new position in shares of Globus Medical in the 2nd quarter worth about $38,000. Finally, Quest Capital Management Inc. ADV purchased a new position in shares of Globus Medical in the 3rd quarter worth about $45,000. 68.40% of the stock is currently owned by hedge funds and other institutional investors.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches.

Featured Story: How does a 12b-1 fee affect fund performance?

Insider Buying and Selling by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.